Post has attachment
Pharmaceutical, Biotechnology and Medical Device Career Fair - Edison, NJ

The HireLifeScience.com Career Fair 2017 will take place at Raritan Center - New Jersey Convention & Exposition Center in Edison, NJ. There will be no recruiting agencies participating in this event, making it one of the few times candidates will meet exclusively with direct employers from the life science industries. This means direct access with the exact contacts that will do the interviewing and no middle men!

Exhibiting Companies:
Novo Nordisk, Inc. *Platinum Sponsor*
Merck & Co. Silver Sponsor
Covance Silver Sponsor
AstraZeneca Silver Sponsor
MedImmune
Glenmark Pharmaceuticals, Inc., USA
Daiichi Sankyo, Inc.
LEO Pharma
Integrated Project Management Company, Inc.
Ferring Pharmaceuticals
Nestle Health Science
Catalent Pharma Solutions
NYU Langone Health
Teva Pharmaceuticals
Center for Electroneurodiagnostics
PharmScript
Amicus Therapeutics
Sun Pharma
Sollers
More to come...

Register to attend at http://www.hirelifescience.com/career/
Required qualifications to attend:
Attendance is free. Candidates must possess a 4 year life science related degree and 2 years professional experience working for a Life Science related company. An invitation to attend will be sent if the minimum qualifications are met.

A general overview of job categories companies will be hiring for:
-Research & Development
-Clinical Research
-Laboratory
-Bioinformatics
-Manufacturing
-Medical Device
-Regulatory Affairs
-Pharmaceutical/Medical Device Sales & Marketing
-Pharmaceutical IT

Applicable fields include but are not limited to:

Bioinformatics, Biostatistics, Clinical Research- Drug safety, Laboratory- Animal/Veterinary, Laboratory - QA, Laboratory - QC, Laboratory - Validation, Manufacturing, Process Development, Medical Communications, Medical Device, Regulatory Affairs, All Biology, All Chemistry, Analytical Chemistry, Biochemistry, Biomedical Engineer, Bioprocess Development, Biotherapeutics, Cell Biology, cGMP, Chemical Engineer, Electrical engineer, Genetics, Immunology, Mechanical Engineer, Microbiology, Molecular Biology, Oncology, Pathology, Pharmacology, Synthetic Chemistry, Toxicology, Sales and Marketing, Business Development, Client Services, Medical Liaison, Product Management, Pharmacokinetics, Virology...

Post has attachment
The announcement of sequencing and characterization of 916 Mb size genome of a freshwater snail (Biomphalaria glabrata) opens new dimensions in understanding schistosomiasis as it transmits the disease. The snail plays an important role as it acts an intermediate host in the life cycle of the parasitic disease schistosomiasis, also known as snail fever or "bilharzia". The parasite (blood fluke) takes control of snail's metabolic activities at its early stage and leaves at a later stage to further infect man. The sequencing efforts would enable us understanding interactions between the parasite and snail genetic makeup is crucial in understanding these interactions, therefore, it is possible to cut the snail out of this parasite's life cycle. For more details please visit www.nature.com/articles/ncomms15451.
Photo

Do you think quantum computers will be accessible for the enormous task of sequencing anytime soon? The possibilities of combining present DNA knowledge with the always multiplying speed of multitasking quantum technology is exciting to say the least.

Post has attachment
World’s largest human genomic data portal Repositive closes series A fundraising of £2.5M

Repositive, the company that created the world’s largest portal for accessing human genomic research data, has closed a Series A funding round of £2.5m.

This investment will allow Repositive to expand its commercial offering through the development of premium features for it's fast growing community of platform users worldwide. Alongside this, Repositive will invest further in expanding the range of data sources on its platform and developing further commercial products and services for the genomics R&D industry. Repositive welcomes Ananda as lead investor and sees the continued support of Amadeus Capital Partners and Jonathan Milner.

Read the Press Release: https://blog.repositive.io/press-release-repositive-closes-series-a-fundraising-of-2-5-million/

How will investments grow community? https://blog.repositive.io/how-investments-will-grow-the-repositive-community/

Browse Repositive's 1.1 million human genomic datasets: https://discover.repositive.io

Post has attachment

Post has attachment
Hello community, I'm looking for some beta testers on a new free site I just created...

It allows users to enter the date on which their DNA kit was activated, the date that the kit arrived at the lab, the date the lab began processing their kit, and the date the lab was done processing their DNA sample.

Providing your dates here on this website will help you and others who are getting their DNA tested to get a better understanding of current or average wait times.

https://dnaprocessingtime.com/

At this time, we only support AncestryDNA, however, in the next few weeks, we’ll be opening it up for the other popular DNA testing companies.

Post has attachment
The headline is a bit misleading, because the "license" is only the permission to conduct research. Still, it's quite significant in terms of the shift in our ethical outlook - could anyone have guessed in the 20th century that in the 21st century we will be researching the modification of human genetics?

http://www.dw.com/en/uk-grants-first-license-for-gm-embryos/a-19015844

Post has attachment

Post has attachment
Really confused with the pricing structure of the GridION

In the link for the GridION page, Nanopore has now made it clear that there is a 450 limit for the discounted flowcells at $299

In that case you would need to be really bad at math to go for CapEx whatever your run-rate!

I have created a chart to show this

https://docs.google.com/spreadsheets/d/1YpKZp9WP8YmNaBfYtpklulQJCdLH6XcmJ_XzR9zMdls/pubchart?oid=522361220&format=image

I have included an option that, in my view would make the CapEx version a viable option. Which would be to make the 1st X number of flowcells free with the product.

If it offered around 80 flowcells for free, the price point for both purchases models would converge at about 550 flowcells (300K)

Since the OpEx mode requires an initial purchase of at least 300 flowcells and the CapEx has no such limit then the CapEx mode might be a viable option for companies not certain about their run rate.

However, without some significant amount of free flowcells, there is absolutely no reason for the CapEx unless you just like spending money.

What the hell am I missing +Oxford Nanopore Technologies​​​​ ?


https://nanoporetech.com/products/gridion

Post has attachment
Could cyclically reoccurring periodic features be at least as important as linear trends in time series plot analysis?


Could it be that cyclically reoccurring periodic osculation patterns and features - no matter how transient - carry more informational value when inferring functional and regulatory aspects based on time series plots compared to potentially underlying linear trends to which most of us have limited most of our attention in the past?

When looking up the same pathway for the attached 81 Time Points (TP) and 8 lifespan datasets it can be clearly shown that the 81 time points for measuring the transcription 26 times per hour. This is the only way to ensure that the time span between subsequent transcriptome measurements would never exceed 3 minutes. Only then even very brief - but nevertheless highly distinctively regulatory and functionally relevant osculating periods could be considered, especially when otherwise too many plots would look the same.


As the gaps between time points keep rising the correlations between time series curves belonging to the same GO terms keeps gradually declining until plots of the same GO term or pathway no longer appear more correlated and similar to one another than to the remaining genome. Exactly, when this point is reached no more functional and regulatory inferences should be based on time series plots. Will therefore inferences not considering relevant cyclically recurring oscillation periods always be wrong, especially if this would cause too many plots to look too much the same?

The data, from which the attached microarray time series plots have been drawn using R, comes from:

https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE30053

It has the title:

Dynamics of two oscillation phenotypes in S. cerevisiae reveal a network of genome-wide transcriptional and cell cycle oscillators

The publication about this dataset is:


Chin SL, Marcus IM, Klevecz RR, Li CM. Dynamics of oscillatory phenotypes in Saccharomyces cerevisiae reveal a network of genome-wide transcriptional oscillators. FEBS J 2012 Mar;279(6):1119-30. PMID: 22289124.

The link to it is:

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368069/

Therefore, one could hypothesize that regulatory and functional inferences based on time series plots should only be considered if the time between subsequent measurements is much shorter than the briefest - but nevertheless functionally and regulatory relevant - difference in osculation patterns.

The maximally acceptable time span between subsequent measurements, which would still allow to make meaningful functional and regulatory inferences based on time series plot similarities, still needs to be experimentally determined because it depends on the overall duration of the cell cycle for each species.

This, in turn, implies that the cyclical nature of periodically reoccurring oscillation patterns tends to over-shadow and thus disguises any potentially underlying linear gene expression trend over time, to which most anti-aging investigators limited most of their attention.

Another informational dimension to highly interdependent time series plots as described above could be added by dividing the GEDI tool into different expression trend regions for better replicating and validating Janssen's conclusion that the proteome will be less similar to the transcriptome later in life when compared to its beginning.

See:

Gabriel S. Eichler, Sui Huang, Donald E. Ingber; Gene Expression Dynamics Inspector (GEDI): for integrative analysis of expression profiles. Bioinformatics 2003; 19 (17): 2321-2322. doi: 10.1093/bioinformatics/btg307

But when I tried to validate this claim by Janssen I found about as many converging as diverging genes. This requires to carefully reproduce Janssen's understandings and concepts of the terms "divergence" and "convergence" and how they were quantified.

See:

Janssens, G. E., Meinema, A. C., González, J., Wolters, J. C., Schmidt, A., Guryev, V., Bischoff, R., Wit, E. C., Veenhoff, L. M., and Heinemann, M. (2015). Protein biogenesis machinery is a driver of replicative aging in yeast. eLife, 4:e08527+.

Could all this lead to the more general conclusion that functional and regulatory inferences based on time series similarities must be flawed when the measuring time points are to far apart for capturing functionally and regulatory relevant periodically reoccurring transient osculation patterns without which it would have been impossible to discern between otherwise identical plots because this would result in functionally unrelated genes to be erroneously placed into the same group?

Thanks

Thomas


Since my text to speech software, on which I am depending because I am almost blind, cannot read out this site to me properly, could you please reply directly to my email, which is TFHahn@UALR.edu
Wait while more posts are being loaded